

HRA Clinical Trials Membership Survey Results

A survey was sent to the Health Research Alliance (HRA) membership (100+ nonprofit funders of biomedical and health research) via the HRA Info email listserv in March 2024 to gather information about member organizations' activities and interest related to clinical trials. This information is intended to be used to inform the activities of the Clinical Trials Interest Group. The survey received 23 responses from 22 HRA member organizations as of 4/1/24. The results of the fixed-response questions are displayed below.

Which of the following best describes your organization's involvement in clinical trials?

(Select all that apply)

Answer	%	# of Responses
We fund clinical trial research	86.96%	20
We help connect patients to appropriate trials	78.26%	18
We help educate patients about clinical trials	73.91%	17
We partner with pharma to support clinical trials	56.52%	13
We help enroll patients in clinical trials	34.78%	8
Members of our organization are investigators for clinical trials	30.43%	7
We sponsor clinical trials	17.39%	4
We lead clinical operations for clinical trials	8.70%	2

How long has your organization been involved in the area of clinical trials?

Answer	%	# of Responses
Less than 1 year	4.35%	1
1 - 5 years	26.09%	6
More than 5 years	69.57%	16

(continued on next page)

What types of clinical trials does your organization focus on?

(Select all that apply.) 2 respondents skipped this question.

Answer	%	# of Responses
Phase I interventional/IND trials	80.95%	17
Phase II interventional/IND trials	71.43%	15
Phase III interventional/IND trials and above	61.90%	13
Non-drug or Non-pharmacological intervention trials	71.43%	15
Observational or Real World data collection studies	76.19%	16

What topics related to clinical trials would you most be interested in learning more about/connecting over during learning community sessions?

(Please choose your top 3 interests, or add your own in the comment box.)

Answer	%	# of Responses
Barriers or best practices for clinical trial implementation	47.83%	11
Innovative clinical trial design paradigms (decentralized trial designs, etc.)	47.83%	11
Clinical trial participant diversity	43.48%	10
Barriers or supports to clinical trial participation for patients	43.83%	10
Clinical trial funding	39.13%	9
Patient recruitment	26.09%	6
Provider awareness about trials	17.39%	4
Helping patients/caregivers find clinical trial information	13.04%	3
Clinical trial field site diversity	8.70%	2
Clinical trial operations/management	4.35%	1

Other (please describe):

- Giving our preclinical academic scientists tools and a roadmap to advance to clinical trials. They weren't trained in how to start a clinical trial
- Clinical trials for ultra-rare disease populations where placebo control is not feasible
- Learning from others who have funded successful studies that did not result in a profit-generating product but did have impact for patients